Pharma Stocks Today: Sun Pharma Gets Relief from US Court, Cipla Gets FDA Approval for Cancer Drug
Current Pharma News: Sun Pharma Gets Favorable US Court Ruling, Cipla Receives FDA Nod for Cancer Drug
Today, Pharma shares went up, with Sun Pharma, Cipla, and Biocon stocks surging by 3% to 4%. The listed companies had some favorable coverage recently which seems to have triggered this sharp movement in the stocks.
Biocon’s Cancer Drug USFDA Approval
Biocon received approval from USFDA for her cancer treatmement Jobevna. The cancer medicine has an estimated market value of USD 2 billion dollars in 2023. As a result of this, Biocon is expected to generate USD 63 million in FY26 and increase that to USD 88 million in FY27.
Sun Pharma Gets Court Relief
The US court gave Sun Pharma good news. The company was able to successfully sue Incyte and lift the ban on marketing Leqselvi, a hair loss treatment drug. Now the company has a few more steps to work through before the launch decision can be announced, which has yet to be revealed.
Cipla’s Cancer Drug Gets FDA Approval
Cipla has finally received the USFDA’s sign off on marketing generic Abraxane. The generic version Paclitaxel is indicated for treatment of breast cancer. Cipla plans to commercialize this drug in the first half of FY26.
Positive Outlook by Elara Capital
Elara Capital believes that this FDA approval is a positive sign for Cipla. According to Cipla’s guidance, they are preparing to launch the drug in H1FY26. The company expects to earn $20 million in the US market during FY26. Currently, 3–4 other generic players are already selling this drug. Still, Cipla hopes to make up to $50 million from this product.
Conclusion
Positive news has fueled an uptick in the pharma sector stocks. With Biocon getting USFDA approval, Sun Pharma winning the court battle, and the green flag given to Cipla for the cancer drug, investor sentiments are more optimistic. These reports indicate a promising outlook for Indian pharma companies globally.
